A hedge fund founded in 2001 and based in the eastern United States has raised a total of $250 million and is currently making investments out of it 4th fund of $35 million. The firm looks to provide equity, convertible note and PIPE financings to mid and late stage companies in the life science space. Initial investments tend to range from $2-$3 million and the firm tends to invest anywhere from $3-$5 million over the lifetime of the investment. The firm is looking for companies located in the US, Canada, Europe, China and Australia and makes approximately 4-5 investments each year.
The firm is looking for companies in sectors of Biotech Therapeutics, Diagnostics and Medical Technology. The firm is open to review almost all indications and subsectors but is particularly interested in areas of immunotherapy, cardiac devices, oncology, cell based therapies, small molecules, proteins, stem cells, and biogenetics. The firm is not interested in orthopedics. The firm is looking for companies that at least have clinical data, and will only evaluate certain preclinical stage assets if the pre-clinical data has some clinical viability.
The firm is looking for companies with experienced complete management teams in place. The firm is very interested in companies that are publically traded and will also invest in privately held companies. As the firm is a cross over investor they look to provide expansion capital and is not interested in company creation investments. The firm generally does not look to take a board seat but does act as a very hands-on investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment